You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of Percutaneous DLC for Total Cavo pulmonary Assistance

    SBC: W-Z BIOTECH LLC            Topic: NHLBI

    DESCRIPTION provided by applicant The Fontan procedure or total cavopulmonary connection TCPC is a standard palliative surgery for patients with complex single ventricle congenital heart anomalies TCPC connects the inferior and superior vena cava IVC and SVC directly to the right pulmonary artery bypassing the heart The single ventricle is then reserved for pumping oxygenated blood to th ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Mutant transgenic plant cells as a novel source of drugs

    SBC: NAPROGENIX, INC.            Topic: 150

    Abstract of administrative supplement The original objective was to use a novel plant biotechnologytarget directed evolutionto produce novel inhibitors of the human dopamine transporterDATas leads for medications for alcohol use disorderThis approach evolves plant biosynthesis toward a specific target by a combination of mutagenesis and selectionLobelia cardinalis was used as the plant species bec ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. A Predictive In Vitro Model for Screening Personalized Responses to CFTR-directed Therapeutics

    SBC: CFD RESEARCH CORPORATION            Topic: NHLBI

    Abstract The objective of this study is to develop a novel predictive in vitro model for personalized responses to CFTR directed therapeutics This proposal responds to RFA HL Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator Directed Therapeutics Cystic fibrosis CF is a life shortening genetic disease caused by loss of ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Ras inhibitor prodrug for colorectal cancer

    SBC: ADT Pharmaceuticals, LLC            Topic: 102

    DESCRIPTION provided by applicant Mutations in the ras family of genes were first identified in human cancer over years ago Such mutations result in the constitutive activation of one or more of three major Ras protein isoforms including H Ras N Ras or K Ras that mediate important signaling pathways leading to uncontrolled cell growth and tumor development Activating ras gene mutations ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Oral sustained-release IL-10 microspheres for therapy of IBD

    SBC: THERAPYX, INC.            Topic: 300

    Abstract The disorders collectively known as inflammatory bowel disease IBD including Crohn s disease CD and ulcerative colitis UC affect up to one and a half million Americans Both result from uncontrolled chronic inflammatory activity in the GI tract Most therapeutic agents act by down regulating inflammation are not curative and suffer from significant side effects Forty to of pat ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Access Control Policy Tool

    SBC: INFOBEYOND TECHNOLOGY LLC            Topic: 90302

    Access Control (AC) determines the permission of a request in attempt to access certain resources in a software system. It has been greatly used for financial, security, privacy, safety, defense, and many other applications. However, there is no commercial‐ready tool to conveniently and thoroughly compose, test, and verify the policies against potential vulnerabilities. In this project, InfoBeyo ...

    SBIR Phase II 2016 Department of CommerceNational Institute of Standards and Technology
  8. Glycosaminoglycan Interacting Small Molecule GISMO as Parkinson s Therapeutic

    SBC: GISMO THERAPEUTICS INC.            Topic: 106

    Glycosaminoglycan Interacting Small Molecule GISMO As Parkinsonandapos s Therapeutics ABSTRACT Current approved drugs for Parkinsonandapos s Disease PD treat the symptoms of the disease but do not stop disease progression This project is focused on developing a new disease modifying PD therapeutic with a novel mode of action that is expected to block disease progression Recent data indicate ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Implantable Optical Intraocular Pressure Sensor for Improved Glaucoma Treatment

    SBC: Brockman-Hastings LLC            Topic: NEI

    PROJECT SUMMARY ABSTRACT Brockman Hastings LLC seeks to reduce vision loss for glaucoma sufferers by creating a simple accurate and clinically acceptable system for monitoring intraocular pressure IOP Trends indicate that by approximately million people worldwide will have glaucoma million of whom will become blind Elevated IOP remains the key risk factor and treated symptom for ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. A New Technique for Diabetic Foot Ulcers

    SBC: Noveratech L.L.C.            Topic: 200

    ABSTRACT Diabetes is the leading cause of nontraumatic lower extremity amputations in the United States Diabetic foot ulcers DFUs are responsible for more hospitalizations than any other diabetic complications Currently even the best available treatments achieve only a healing rate for these wounds and this healing is often only temporary with a chance of recurring Our company has ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government